Hi insulsaSorry for the delay but I have gathered mor...

Hi insulsa
Sorry for the delay
but I have gathered mor information re Duvyzat in competition with Atl1102

Like I said it was good news on Friday. PER does not see a lot of competition between ATL1102 and givinostat for a couple of reasons.
First, all the givinostat data is in ambulant patients. We haven’t seen the label yet, but it is very likely that, even if FDA doesn’t restrict use to this population, payors will. ATL1102, of course, is currently being developed for non-ambulant patients
. Second, there are some meaningful toxicities with HDAC inhibitors, including gastrointestinal toxicity, and we suspect that a proportion of patients won’t be able to tolerate the drug for long-term use
. Finally, to the extent that there are patients who would be eligible for both drugs
Like I said previously it is likely that clinicians will ultimately look to use them in combination.
Overall, I think this is a positive for the DMD community and effectively neutral to positive for ATL1102.
Yes ! I don’t see it as a problem but we’re on the the right track re inflammation .